exidavnemab

DRUG2 trials

Sponsors

BioArctic AB

Conditions

Multiple System AtrophyParkinson DiseaseParkinson’s Disease (PD)

Phase 2

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease on Stable Symptomatic Parkinson’s Disease Medication and in Patients with Multiple System Atrophy

RecruitingCTIS2024-511222-30-00

BioArctic ABMultiple System Atrophy, Parkinson’s Disease (PD)

Start: 2024-10-22Target: 36Updated: 2025-05-26

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

CompletedNCT06671938

BioArctic ABMultiple System Atrophy, Parkinson Disease

Start: 2024-10-24End: 2026-08-10Updated: 2026-08-21